Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Addex Therapeutics Ltd ADXN
$0.90
+$0.01 (1.23%)
На 18:01, 12 мая 2023
+1 566.67%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
12202760.00000000
-
week52high
4.34
-
week52low
0.55
-
Revenue
1422438
-
P/E TTM
-1
-
Beta
1.71374000
-
EPS
-3.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 мар 2023 г. в 04:00
Описание компании
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 23 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 31 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 февр 2022 г. |
| HC Wainwright & Co. | Buy | 21 апр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Addex Therapeutics Ltd (ADXN) Q3 2022 Earnings Call Transcript
Seeking Alpha
11 ноя 2022 г. в 14:36
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2022 Results Conference Call November 11, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Rob Lütjens - Head of Discovery, Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Tim Dyer Hello everyone. I'd like to thank you all for joining our Quarter Three 2022 Financial Results Conference Call.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
11 ноя 2022 г. в 08:17
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022.
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
GlobeNewsWire
03 ноя 2022 г. в 02:00
Geneva, Switzerland, November 3 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its third quarter 2022 financial results on Friday, November 11, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 11:00 EDT / 08:00 PDT) the same day.
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
GlobeNewsWire
20 сент 2022 г. в 01:00
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.
Addex Therapeutics Ltd (ADXN) CEO Tim Dyer on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
18 авг 2022 г. в 15:50
Start Time: 10:00 January 1, 0000 10:41 AM ET Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2022 Earnings Conference Call August 18, 2022, 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call.